XML 40 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheet Details (Tables)
12 Months Ended
Dec. 31, 2018
Condensed Financial Information Disclosure [Abstract]  
Short Term Marketable Securities
Short-Term Marketable Securities
Short-term marketable securities, consisting of equity securities and debt securities, were as follows as of the dates indicated: 
 
December 31, 2018
(In millions)
Cost or Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
Equity investment in Tandem Diabetes Care, Inc
$
2.0

 
$
36.0

 
$

 
$
38.0

 
 
 
 
 
 
 
 
Debt securities, available for sale:
 
 
 
 
 
 
 
U.S. government agencies
173.2

 

 
(0.1
)
 
173.1

Commercial paper
36.2

 

 

 
36.2

Corporate debt
1.3

 

 

 
1.3

Total debt securities, available for sale
210.7

 

 
(0.1
)
 
210.6

 
 
 
 
 
 
 
 
Total marketable securities
$
212.7

 
$
36.0

 
$
(0.1
)
 
$
248.6


 
 
December 31, 2017
(In millions)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
Debt securities, available for sale:
 
 
 
 
 
 
 
U.S. government agencies
$
87.5

 
$

 
$
(0.2
)
 
$
87.3

Commercial paper
14.7

 

 

 
14.7

Corporate debt
5.1

 

 

 
5.1

Total debt securities, available for sale
$
107.3

 
$

 
$
(0.2
)
 
$
107.1

Reconciliation of net gain realized and unrealized gain recognized on equity securities
The following table reconciles the net gain recognized on equity securities during the twelve months ended December 31, 2018, 2017 and 2016 to the unrealized gain recognized during those periods on equity securities still held at the reporting dates.
 
Twelve Months Ended 
 December 31,
(In millions)
2018
 
2017
 
2016
Net gains recognized during the period on equity securities
$
80.1

 
$

 
$

Less: Net gains recognized during the period on equity securities sold during the period
(44.1
)
 

 

Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$
36.0

 
$

 
$

Accounts Receivable
Accounts Receivable
 
December 31,
(In millions)
2018
 
2017
Accounts receivable
$
233.9

 
$
145.8

Less allowance for doubtful accounts
(7.2
)
 
(11.5
)
Total accounts receivable, net
$
226.7

 
$
134.3

Inventory
Inventory 
 
December 31,
(In millions)
2018
 
2017
Raw materials
$
30.8

 
$
20.0

Work-in-process
11.2

 
8.2

Finished goods
28.7

 
17.0

Total inventory
$
70.7

 
$
45.2

Property and Equipment
Property and Equipment
 
December 31,
(In millions)
2018
 
2017
Building (1)
$
6.0

 
$
6.0

Furniture and fixtures
9.0

 
5.7

Computer software and hardware
29.2

 
25.6

Machinery and equipment
80.7

 
33.8

Leasehold improvements
80.7

 
41.7

Construction in progress (2)
57.3

 
87.6

Total cost
262.9

 
200.4

Less accumulated depreciation and amortization
(79.8
)
 
(54.8
)
Total property and equipment, net
$
183.1

 
$
145.6


(1) As described in Note 6, “Commitments,” although we do not legally own these premises, we were deemed the owner of the construction project during the construction period of our manufacturing facility in Mesa, Arizona under a build-to suit lease arrangement. We placed the facility into service in 2018 and as of December 31, 2018 had recorded accumulated amortization of $0.7 million.
(2) Construction in progress as of December 31, 2018 and December 31, 2017 included approximately $6.2 million and $33.6 million, respectively, related to our manufacturing facility in Mesa, Arizona with the remaining balances as of those dates primarily related to machinery and equipment.
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities 
 
December 31,
(In millions)
2018
 
2017
Accounts payable trade
$
75.5

 
$
46.7

Accrued tax, audit, and legal fees
11.7

 
7.1

Accrued rebates
36.1

 
13.9

Accrued warranty
6.8

 
8.8

Accrued other
17.0

 
10.7

Total accounts payable and accrued liabilities
$
147.1

 
$
87.2

Accrued Warranty
Accrued Warranty
Warranty costs are reflected in our statements of operations as cost of product sales. Reconciliations of our accrued warranty costs for the twelve months ended December 31, 2018 and 2017 were as follows:
 
Twelve Months Ended
December 31,
(In millions)
2018
 
2017
Beginning balance
$
8.8

 
$
9.8

Charges to costs and expenses
17.4

 
18.4

Costs incurred
(19.4
)
 
(19.4
)
Ending balance
$
6.8

 
$
8.8

Schedule of Other Assets and Other Liabilities
Other Liabilities
 
December 31,
(In millions)
2018
 
2017
Financing lease obligations
$
7.3

 
$
6.7

Deferred rent
9.4

 
8.7

Other
3.3

 
2.8

Total other liabilities
$
20.0

 
$
18.2